Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$28.6 million.

  • Lyell Immunopharma's Cash from Operations rose 1844.93% to -$28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$165.0 million, marking a year-over-year decrease of 592.35%. This contributed to the annual value of -$162.4 million for FY2024, which is 79.42% up from last year.
  • Lyell Immunopharma's Cash from Operations amounted to -$28.6 million in Q3 2025, which was up 1844.93% from -$34.5 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Cash from Operations registered a high of -$25.5 million during Q3 2021, and its lowest value of -$54.7 million during Q1 2025.
  • In the last 5 years, Lyell Immunopharma's Cash from Operations had a median value of -$38.1 million in 2024 and averaged -$38.9 million.
  • Per our database at Business Quant, Lyell Immunopharma's Cash from Operations crashed by 4554.76% in 2022 and then surged by 1844.93% in 2025.
  • Lyell Immunopharma's Cash from Operations (Quarter) stood at -$33.2 million in 2021, then fell by 21.24% to -$40.3 million in 2022, then dropped by 0.91% to -$40.6 million in 2023, then fell by 16.26% to -$47.2 million in 2024, then surged by 39.51% to -$28.6 million in 2025.
  • Its Cash from Operations was -$28.6 million in Q3 2025, compared to -$34.5 million in Q2 2025 and -$54.7 million in Q1 2025.